One-year effectiveness and safety of vedolizumab therapy for inflammatory bowel disease: a prospective multicentre cohort study.

Aurélien AmiotM SerreroL Peyrin-BirouletJ FilippiB ParienteXavier Roblin Anthony BuissonC StefanescuC Trang-PoissonR AltweggP MarteauT VaysseA BourrierS NanceyD LaharieM AllezG SavoyeJ MoreauL VuittonS ViennotA AubourgA-L PelletierG BouguenV AbitbolC GagniereY Bouhniknull null

Published in: Alimentary pharmacology & therapeutics (2017)

Vedolizumab is able to maintain steroid-free clinical remission in up to one-third of patients with UC and CD at week 54 with a reasonable safety profile. A significant number of patients experienced loss of response during the first year of treatment, particularly in patients with CD.

Keyphrases

ulcerative colitis
end stage renal disease
ejection fraction
newly diagnosed
clinical trial
patients with inflammatory bowel disease
peritoneal dialysis
prognostic factors
randomized controlled trial
nk cells
cross sectional
combination therapy
patient reported